Advertisement
Home Tags Drug Approvals

Tag: Drug Approvals

A new antipsychotic drug to treat schizophrenia and bipolar disorder in adults has been approved by the U.S. Food and Drug Administration. The drug

FDA Approves New Drug for Schizophrenia, Bipolar Disorder

0
Vraylar is an atypical antipsychotic taken once a day
Varubi (rolapitant) has been approved by the U.S. Food and Drug Administration to prevent delayed phase chemotherapy-induced nausea and vomiting.

FDA Approves Varubi for Chemo-Induced Nausea, Vomiting

0
For prevention of the delayed phase of nausea, vomiting caused by chemotherapy
Repatha (evolocumab) has been approved by the U.S. Food and Drug Administration

FDA Approves Repatha for Certain Patients With High Cholesterol

0
Approved for patients unable to get LDL cholesterol under control with current treatment options
U.S. Food and Drug Administration approval of the drug Promacta (eltrombopag) has been expanded to include children 1 year and older with chronic immune thrombocytopenic purpura.

Promacta Approval Expanded for Children With Chronic ITP

0
Builds on recent approval for ages 6 years and up for chronic immune thrombocytopenic purpura
Addyi (flibanserin) has been approved by the U.S. Food and Drug Administration as the first drug to treat generalized hypoactive sexual desire disorder among premenopausal women. The drug is for women who do not have an underlying physical or psychological cause for the disorder

FDA Approves Libido Pill for Women

0
Addyi to treat generalized hypoactive sexual desire disorder among premenopausal women
The ReShape Integrated Dual Balloon System has been approved by the U.S. Food and Drug Administration to combat adult obesity. Inflated inside the stomach

FDA Approves Balloon Device to Treat Obesity

0
Inflated in stomach, it may create sense of fullness
Praluent (alirocumab) injection has been approved by the U.S. Food and Drug Administration for use in addition to diet and maximally tolerated statin therapy in adults with heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease

FDA Approves Praluent for Certain Cases of High Cholesterol

0
First in a new class of injectable cholesterol-lowering medications
A new diagnostic to differentiate between HIV-1 antibodies

FDA Approves Test to Differentiate HIV Viruses

0
Among people two years and older
Technivie (ombitasvir

FDA Approves Technivie for Hepatitis C

0
For people with chronic hepatitis C genotype 4
Odomzo (sonidegib) has been approved by the U.S. Food and Drug Administration to treat locally advanced basal cell carcinoma that has returned despite surgery or radiation. The treatment is sanctioned for people who are not candidates for additional surgery or radiation.

FDA Approves Odomzo for Recurring Basal Cell Carcinoma

0
Medication is designed to inhibit the Hedgehog pathway